These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 9184402

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim.
    van Der Auwera P, Platzer E, Xu ZX, Schulz R, Feugeas O, Capdeville R, Edwards DJ.
    Am J Hematol; 2001 Apr; 66(4):245-51. PubMed ID: 11279634
    [Abstract] [Full Text] [Related]

  • 44. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R, Grebe S.
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [Abstract] [Full Text] [Related]

  • 45. Antithrombotic and bleeding effects of a new synthetic direct thrombin inhibitor and of standard heparin in the rabbit.
    Cadroy Y, Caranobe C, Bernat A, Maffrand JP, Sié P, Boneu B.
    Thromb Haemost; 1987 Aug 04; 58(2):764-7. PubMed ID: 3672429
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
    Hafner G, Rupprecht HJ, Luz M, Terres W, Schindel F, Friesen HJ, Heinrichs H, Jessel A, Meyer J, Prellwitz W.
    Eur Heart J; 1996 Aug 04; 17(8):1207-15. PubMed ID: 8869862
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. High and constant plasma levels of tissue plasminogen activator and PEG-hirudin can be achieved by subcutaneous delivery.
    Humphries J, Lattimer C, Smith A, McGuinness CL, Whitton C, Gaffney PJ, Burnand KG.
    Thromb Res; 1997 Jul 01; 87(1):123-9. PubMed ID: 9253807
    [Abstract] [Full Text] [Related]

  • 51. Pharmacokinetic studies with recombinant hirudin in dogs.
    Nowak G, Markwardt F, Fink E.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988 Jul 01; 115(1-2):70-4. PubMed ID: 2459035
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Influence of piroxicam coadministration on pharmacodynamic parameters and the plasma concentration/effect relationship of recombinant hirudin (CGP 39393).
    Thürmann P, Harder S, Kirchmaier CM.
    Eur J Clin Pharmacol; 1995 Jul 01; 48(3-4):241-6. PubMed ID: 7589048
    [Abstract] [Full Text] [Related]

  • 55. DDAVP reduces bleeding during continued hirudin administration in the rabbit.
    Bove CM, Casey B, Marder VJ.
    Thromb Haemost; 1996 Mar 01; 75(3):471-5. PubMed ID: 8701410
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Anti-thrombotic effects of CX-397, a recombinant hirudin analog, in a canine model of coronary artery thrombosis.
    Ohyama T, Hori T, Moriike M, Asano T, Hayashi H, Iwade K, Hosoda S.
    Thromb Haemost; 1998 Feb 01; 79(2):423-30. PubMed ID: 9493602
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Activated coagulation time in monitoring heparinized dogs.
    Green RA.
    Am J Vet Res; 1980 Nov 01; 41(11):1793-7. PubMed ID: 7212408
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.